173 related articles for article (PubMed ID: 11751060)
1. Biology of the gonadotropin-releasing hormone system in gynecological cancers.
Gründker C; Günthert AR; Westphalen S; Emons G
Eur J Endocrinol; 2002 Jan; 146(1):1-14. PubMed ID: 11751060
[TBL] [Abstract][Full Text] [Related]
2. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
Gründker C; Emons G
Reprod Biol Endocrinol; 2003 Oct; 1():65. PubMed ID: 14594454
[TBL] [Abstract][Full Text] [Related]
3. GnRH antagonists in the treatment of gynecological and breast cancers.
Emons G; Gründker C; Günthert AR; Westphalen S; Kavanagh J; Verschraegen C
Endocr Relat Cancer; 2003 Jun; 10(2):291-9. PubMed ID: 12790790
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin.
Gründker C; Schlotawa L; Viereck V; Emons G
Eur J Endocrinol; 2001 Nov; 145(5):651-8. PubMed ID: 11720885
[TBL] [Abstract][Full Text] [Related]
5. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells.
Emons G; Müller V; Ortmann O; Schulz KD
J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):199-206. PubMed ID: 9699874
[TBL] [Abstract][Full Text] [Related]
6. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
7. The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis.
Gründker C; Emons G
Front Endocrinol (Lausanne); 2017; 8():187. PubMed ID: 28824547
[TBL] [Abstract][Full Text] [Related]
8. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
9. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
[TBL] [Abstract][Full Text] [Related]
10. Growth-inhibitory actions of analogues of Luteinizing Hormone Releasing Hormone on tumor cells.
Emons G; Ortmann O; Schulz KD; Schally AV
Trends Endocrinol Metab; 1997 Nov; 8(9):355-62. PubMed ID: 18406825
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Gründker C; Völker P; Emons G
Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
Fister S; Günthert AR; Emons G; Gründker C
Cancer Res; 2007 Feb; 67(4):1750-6. PubMed ID: 17308117
[TBL] [Abstract][Full Text] [Related]
13. GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells.
Eicke N; Günthert AR; Emons G; Gründker C
Int J Oncol; 2006 Nov; 29(5):1223-9. PubMed ID: 17016655
[TBL] [Abstract][Full Text] [Related]
14. The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans.
Limonta P; Moretti RM; Montagnani Marelli M; Motta M
Front Neuroendocrinol; 2003 Dec; 24(4):279-95. PubMed ID: 14726258
[TBL] [Abstract][Full Text] [Related]
15. Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium.
Kang SK; Choi KC; Cheng KW; Nathwani PS; Auersperg N; Leung PC
Endocrinology; 2000 Jan; 141(1):72-80. PubMed ID: 10614625
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
Gründker C; Schlotawa L; Viereck V; Eicke N; Horst A; Kairies B; Emons G
Eur J Endocrinol; 2004 Jul; 151(1):141-9. PubMed ID: 15248835
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview.
So WK; Cheng JC; Poon SL; Leung PC
FEBS J; 2008 Nov; 275(22):5496-511. PubMed ID: 18959739
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells.
Gründker C; Günthert AR; Hellriegel M; Emons G
Eur J Endocrinol; 2004 Nov; 151(5):619-28. PubMed ID: 15538941
[TBL] [Abstract][Full Text] [Related]
19. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor.
Maudsley S; Davidson L; Pawson AJ; Chan R; López de Maturana R; Millar RP
Cancer Res; 2004 Oct; 64(20):7533-44. PubMed ID: 15492280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
